Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1982 1
1984 2
1985 2
1986 1
1987 1
1988 2
1989 3
1990 2
1991 3
1992 1
1993 1
1995 2
1997 2
1999 1
2000 3
2007 1
2009 1
2010 2
2011 3
2012 12
2013 13
2014 9
2015 7
2016 13
2017 16
2018 14
2019 22
2020 31
2021 26
2022 26
2023 16
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

233 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, Wapnir IL, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, Wülfing P, Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, Geyer CE Jr; KATHERINE Investigators. von Minckwitz G, et al. N Engl J Med. 2019 Feb 14;380(7):617-628. doi: 10.1056/NEJMoa1814017. Epub 2018 Dec 5. N Engl J Med. 2019. PMID: 30516102 Clinical Trial.
Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer.
Shitara K, Ajani JA, Moehler M, Garrido M, Gallardo C, Shen L, Yamaguchi K, Wyrwicz L, Skoczylas T, Bragagnoli AC, Liu T, Tehfe M, Elimova E, Bruges R, Zander T, de Azevedo S, Kowalyszyn R, Pazo-Cid R, Schenker M, Cleary JM, Yanez P, Feeney K, Karamouzis MV, Poulart V, Lei M, Xiao H, Kondo K, Li M, Janjigian YY. Shitara K, et al. Nature. 2022 Mar;603(7903):942-948. doi: 10.1038/s41586-022-04508-4. Epub 2022 Mar 23. Nature. 2022. PMID: 35322232 Free PMC article. Clinical Trial.
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J; APHINITY Steering Committee and Investigators. von Minckwitz G, et al. N Engl J Med. 2017 Jul 13;377(2):122-131. doi: 10.1056/NEJMoa1703643. Epub 2017 Jun 5. N Engl J Med. 2017. PMID: 28581356 Free PMC article. Clinical Trial.
Intravenous Vitamin C in Adults with Sepsis in the Intensive Care Unit.
Lamontagne F, Masse MH, Menard J, Sprague S, Pinto R, Heyland DK, Cook DJ, Battista MC, Day AG, Guyatt GH, Kanji S, Parke R, McGuinness SP, Tirupakuzhi Vijayaraghavan BK, Annane D, Cohen D, Arabi YM, Bolduc B, Marinoff N, Rochwerg B, Millen T, Meade MO, Hand L, Watpool I, Porteous R, Young PJ, D'Aragon F, Belley-Cote EP, Carbonneau E, Clarke F, Maslove DM, Hunt M, Chassé M, Lebrasseur M, Lauzier F, Mehta S, Quiroz-Martinez H, Rewa OG, Charbonney E, Seely AJE, Kutsogiannis DJ, LeBlanc R, Mekontso-Dessap A, Mele TS, Turgeon AF, Wood G, Kohli SS, Shahin J, Twardowski P, Adhikari NKJ; LOVIT Investigators and the Canadian Critical Care Trials Group. Lamontagne F, et al. N Engl J Med. 2022 Jun 23;386(25):2387-2398. doi: 10.1056/NEJMoa2200644. Epub 2022 Jun 15. N Engl J Med. 2022. PMID: 35704292 Clinical Trial.
A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis.
Zou Y, Palte MJ, Deik AA, Li H, Eaton JK, Wang W, Tseng YY, Deasy R, Kost-Alimova M, Dančík V, Leshchiner ES, Viswanathan VS, Signoretti S, Choueiri TK, Boehm JS, Wagner BK, Doench JG, Clish CB, Clemons PA, Schreiber SL. Zou Y, et al. Nat Commun. 2019 Apr 8;10(1):1617. doi: 10.1038/s41467-019-09277-9. Nat Commun. 2019. PMID: 30962421 Free PMC article.
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.
Telli ML, Timms KM, Reid J, Hennessy B, Mills GB, Jensen KC, Szallasi Z, Barry WT, Winer EP, Tung NM, Isakoff SJ, Ryan PD, Greene-Colozzi A, Gutin A, Sangale Z, Iliev D, Neff C, Abkevich V, Jones JT, Lanchbury JS, Hartman AR, Garber JE, Ford JM, Silver DP, Richardson AL. Telli ML, et al. Clin Cancer Res. 2016 Aug 1;22(15):3764-73. doi: 10.1158/1078-0432.CCR-15-2477. Epub 2016 Mar 8. Clin Cancer Res. 2016. PMID: 26957554 Free PMC article. Clinical Trial.
Management of immune-related cutaneous adverse events with dupilumab.
Kuo AM, Gu S, Stoll J, Moy AP, Dusza SW, Gordon A, Haliasos EC, Janjigian Y, Kraehenbuehl L, Quigley EA, Chapman P, Lacouture ME, Markova A. Kuo AM, et al. J Immunother Cancer. 2023 Jun;11(6):e007324. doi: 10.1136/jitc-2023-007324. J Immunother Cancer. 2023. PMID: 37270183 Free PMC article.
Only 1 patient (2.6%) discontinued therapy due to AEs, specifically, injection site reaction. Average eosinophil counts decreased by 0.2 K/mcL (p=0.0086). Relative eosinophils decreased by a mean of 2.6% (p=0.0152). ...
Only 1 patient (2.6%) discontinued therapy due to AEs, specifically, injection site reaction. Average eosinophil counts decreased by 0.2 …
Observation of B_{c}^{+}D^{0}K^{+} Decays.
Aaij R, Adeva B, Adinolfi M, Ajaltouni Z, Akar S, Albrecht J, Alessio F, Alexander M, Ali S, Alkhazov G, Alvarez Cartelle P, Alves AA, Amato S, Amerio S, Amhis Y, An L, Anderlini L, Andreassi G, Andreotti M, Andrews JE, Appleby RB, Archilli F, d'Argent P, Arnau Romeu J, Artamonov A, Artuso M, Aslanides E, Auriemma G, Baalouch M, Babuschkin I, Bachmann S, Back JJ, Badalov A, Baesso C, Baker S, Balagura V, Baldini W, Barlow RJ, Barschel C, Barsuk S, Barter W, Baryshnikov F, Baszczyk M, Batozskaya V, Batsukh B, Battista V, Bay A, Beaucourt L, Beddow J, Bedeschi F, Bediaga I, Bel LJ, Bellee V, Belloli N, Belous K, Belyaev I, Ben-Haim E, Bencivenni G, Benson S, Berezhnoy A, Bernet R, Bertolin A, Betancourt C, Betti F, Bettler MO, van Beuzekom M, Bezshyiko I, Bifani S, Billoir P, Bird T, Birnkraut A, Bitadze A, Bizzeti A, Blake T, Blanc F, Blouw J, Blusk S, Bocci V, Boettcher T, Bondar A, Bondar N, Bonivento W, Bordyuzhin I, Borgheresi A, Borghi S, Borisyak M, Borsato M, Bossu F, Boubdir M, Bowcock TJ, Bowen E, Bozzi C, Braun S, Britsch M, Britton T, Brodzicka J, Buchanan E, Burr C, Bursche A, Buytaert J, Cadeddu S, Calabrese R, Calvi M, Calvo Gomez M, Camboni A, Campana P, Campora Pere… See abstract for full author list ➔ Aaij R, et al. Phys Rev Lett. 2017 Mar 17;118(11):111803. doi: 10.1103/PhysRevLett.118.111803. Epub 2017 Mar 15. Phys Rev Lett. 2017. PMID: 28368647 Free article.
Using proton-proton collision data corresponding to an integrated luminosity of 3.0 fb^{-1}, recorded by the LHCb detector at center-of-mass energies of 7 and 8 TeV, the B_{c}^{+}D^{0}K^{+} decay is observed with a statistical significance of 5.1 standard deviations. By no …
Using proton-proton collision data corresponding to an integrated luminosity of 3.0 fb^{-1}, recorded by the LHCb detector at center-of-mass …
233 results